Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel 

Study Title
Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel
Teva Identifier
NEUGR-002
ClinicalTrials.gov Identifier
NCT00837265
Study Status
Completed
Trial Condition(s)
Chemotherapy-induced Neutropenia
Interventions
Biological: Neugranin | Drug: Pegfilgrastim | Drug: Chemotherapy

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years and older
Trial Duration
08/01/2008 - 07/01/2010
Phase
Phase 2/3

Study Type

Interventional